68164-77-2Relevant articles and documents
EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS
-
Paragraph 0311-0312; 0360, (2021/01/23)
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
-
, (2016/06/21)
Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
Preparation of cyanopyridines by direct cyanation
Katritzky, Alan R.,Scriven, Eric F. V.,Majumder, Suman,Tu, Hongbin,Vakulenko, Anatoliy V.,Akhmedov, Novruz G.,Murugan, Ramiah
, p. 993 - 997 (2007/10/03)
After pretreatment with nitric acid and trifluoroacetic anhydride, aqueous potassium cyanide converted pyridines 1a-1 into their corresponding 2-cyano derivatives 4a-1 in an average yield of 52%. Georg Thieme Verlag Stuttgart.